Kythera Biopharmaceuticals, Inc.

Antibody-drug conjugate (ADC) developer Adcendo has been busy during the last year and a half since the company raised a €31m ($32.3m) extension of the €51m ($53.2m) series A it originally raised in 2

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Allergan Extends Its Aesthet

The unexpected announcement on 25 June that Allergan PLC will be acquired by AbbVie Inc. for $63bn far exceeded expectations that Allergan would appease its investors by splitting the company in t

Allergan PLC finally gave in to activist investor Appaloosa LP's demand that the pharma's CEO and chairman roles be separated, but the decision to give those roles to two different people won't go in